These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12113388)

  • 1. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer.
    Saigal CS; Gornbein J; Reid K; Litwin MS
    Qual Life Res; 2002 Aug; 11(5):405-14. PubMed ID: 12113388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.
    Krahn M; Ritvo P; Irvine J; Tomlinson G; Bremner KE; Bezjak A; Trachtenberg J; Naglie G
    Med Care; 2003 Jan; 41(1):153-64. PubMed ID: 12544552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of the University of California-Los Angeles Prostate Cancer Index.
    Bergman J; Saigal CS; Kwan L; Litwin MS
    Urology; 2010 Jun; 75(6):1418-23. PubMed ID: 19589573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
    J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilities for prostate cancer health states in men aged 60 and older.
    Stewart ST; Lenert L; Bhatnagar V; Kaplan RM
    Med Care; 2005 Apr; 43(4):347-55. PubMed ID: 15778638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting utility scores for prostate cancer: mapping the Prostate Cancer Index to the Patient-Oriented Prostate Utility Scale (PORPUS).
    Bremner KE; Mitsakakis N; Wilson L; Krahn MD
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):47-56. PubMed ID: 24126796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of forecasted assessment of quality of life to validate time-trade-off utilities and a prostate cancer screening decision-analytic model.
    Cantor SB; Deshmukh AA; Krahn MD; Volk RJ
    Health Expect; 2015 Oct; 18(5):1610-20. PubMed ID: 26039695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of utilities for health states in early stage prostate cancer.
    Saigal CS; Gornbein J; Nease R; Litwin MS
    J Urol; 2001 Sep; 166(3):942-6. PubMed ID: 11490251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.
    Krahn MD; Bremner KE; Alibhai SM; Ni A; Tomlinson G; Laporte A; Naglie G
    Qual Life Res; 2013 Dec; 22(10):2951-62. PubMed ID: 23564620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer.
    Bruner DW; Hanlon A; Mazzoni S; Raysor S; Konski A; Hanks G; Pollack A
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):34-42. PubMed ID: 14697418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient preferences for outcomes associated with surgical management of prostate cancer.
    Smith DS; Krygiel J; Nease RF; Sumner W; Catalona WJ
    J Urol; 2002 May; 167(5):2117-22. PubMed ID: 11956454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.
    Meghani SH; Lee CS; Hanlon AL; Bruner DW
    BMC Med Inform Decis Mak; 2009 Nov; 9():47. PubMed ID: 19941668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.
    Porreca A; Noale M; Artibani W; Bassi PF; Bertoni F; Bracarda S; Conti GN; Corvò R; Gacci M; Graziotti P; Magrini SM; Mirone V; Montironi R; Muto G; Pecoraro S; Ricardi U; Russi E; Tubaro A; Zagonel V; Crepaldi G; Maggi S;
    Health Qual Life Outcomes; 2018 Jun; 16(1):122. PubMed ID: 29898750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the preferences of patients with psoriasis. A quantitative, utility approach.
    Zug KA; Littenberg B; Baughman RD; Kneeland T; Nease RF; Sumner W; O'Connor GT; Jones R; Morrison E; Cimis R
    Arch Dermatol; 1995 May; 131(5):561-8. PubMed ID: 7741543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.
    Cooperberg MR; Koppie TM; Lubeck DP; Ye J; Grossfeld GD; Mehta SS; Carroll PR;
    Urology; 2003 Jan; 61(1):190-6. PubMed ID: 12559294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians.
    Bennett CL; Chapman G; Elstein AS; Knight SJ; Nadler RB; Sharifi R; Kuzel T
    Eur Urol; 1997; 32 Suppl 3():86-8. PubMed ID: 9267792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
    Lubeck DP; Grossfeld GD; Carroll PR
    Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-cultural validation of the UCLA prostate cancer index.
    Karakiewicz PI; Kattan MW; Tanguay S; Elhilali MM; Bazinet M; Scardino PT; Aprikian AG
    Urology; 2003 Feb; 61(2):302-7. PubMed ID: 12597935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of voiding function after radical retropubic prostatectomy.
    Namiki S; Ishidoya S; Saito S; Satoh M; Tochigi T; Ioritani N; Yoshimura K; Terai A; Arai Y
    Urology; 2006 Jul; 68(1):142-7. PubMed ID: 16777193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.